Dermatology Drugs Global Market Report 2018

Dermatology Drugs
Global Market Report 2018
Including: Dermatology Drugs
Covering: Johnson & Johnson, Allergan Plc, Galderma S.A, Novartis AG, GlaxoSmithKline Plc
Feb 2018

Reasons to Purchase
• Outperform competitors using accurate up to date demand-side dynamics
information.
• Identify growth segments for investment.
• Facilitate decision making on the basis of historic and forecast data and the
drivers and restraints on the market.
• Create regional and country strategies on the basis of local data and analysis.
• Stay abreast of the latest customer and market research findings
• Benchmark performance against key competitors.
• Develop strategies based on likely future developments.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high
quality data and analysis
• Gain a global perspective on the development of the market.
• Report will be updated with the latest data and delivered to you within 3-5
working days of order.
Scope
Markets Covered: Dermatology Drugs
Companies Mentioned: Johnson & Johnson, Allergan Plc, Galderma S.A, Novartis AG,
GlaxoSmithKline Plc
Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and
Australia.
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America,
Middle East And Africa
Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita,
Dermatology Drugs Indicators Comparison.
Data segmentations: Country and regional historic and forecast data, market share of
competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end
notes.

Dermatology Drugs Market
Characteristics
The dermatology drugs market includes medications that are used for the
treatment of skin conditions such as dermatitis (including eczema), rosacea,
hyperhidrosis, androgenic alopecia, onychomycosis, hair loss, acne, immune
disorders (including psoriasis), microbial infections (bacterial, fungal, and viral),
vascular and pigmented lesion removal, common warts, seborrheic keratosis, and
other skin diseases The market numbers within this briefing are restricted to
pharmaceutical (drug) treatments and do not cover biologic treatments for these
conditions which are included in a separate briefing.
Dermatology drugs used to treat acne include local anesthetics, cleansers, antiinflammatory
agents, anti-infectives, emollients, and astringents. These drugs are
available for both topical (external) use and internal use. These drugs can be sold
as over-the-counter (OTC) as well as prescription drugs. Major OTC dermatological
drugs include Differin, Lamisil, Monistat, and Abreva. Some of the major
dermatology prescription drugs include Clobetasol propionate, Flucinonide,
Baxdela, Siliq, Rhofade.
The segments that are covered include –
Dermatology Drugs –
Topical dermatology drugs are available in a wide range of
In this report market value is defined as the revenues organizations earn by selling
their goods and services within the specified market, based on the price at which
they sell. Only goods and services traded between entities are included.
The revenues for a specified geography are consumption values – that is, they are
revenues generated by organizations in the specified geography within the
specified market, irrespective of where they are produced.

Dermatology Drugs Market
Historic Growth
The global dermatology drugs market grew from $X billion in 2013 to $X billion in
2017 at a compound annual growth rate (CAGR) of X%.
The chart and table below shows the year-on-year growth of the global
dermatology drugs market during 2013 – 2017.
Drivers of the Market:
Restraints on the Market:

Dermatology Drugs Market
Forecast Growth
The global dermatology drugs market is expected to grow from $XX billion in 2017
to $40 billion in 2021 at a compound annual growth rate (CAGR) of XX%. Going
forward, increase in the number of indications treated by topical drugs coupled
with increase in acne and rosacea patients will drive the market for dermatology
drugs.
The chart and table below shows the year-on-year growth of the global
dermatology drugs market during 2017 - 2021.
Drivers of the Market:
Restraints on the Market:

Dermatology Drugs Market
Regional And Country Analysis
The Asia Pacific was the largest region in the dermatology drugs market in 2017,
dermatology drugs for $X billion or 38% market share.
North America was the x largest region dermatology drugs for $X billion or X%
market share.
Western Europe was the x largest region dermatology drugs for $X billion or X%
market share.

Dermatology Drugs Market
Competitive Landscape
The leading competitors in the global dermatology drugs market are Johnson &
Johnson, Allergan Plc, Galderma S.A., Novartis AG, GlaxoSmithKline Plc.
The chart and table below displays the percentage market share of the top players
in the dermatology drugs market industry.
Johnson & Johnson generated revenues of $XX billion for the financial year 2016,
an XX% increase from the previous year.
Allergan Plc. generated revenues of $XX billion for the financial year 2016, an XX%
increase from the previous year.
Galderma S.A. generated revenues of $XX billion for the financial year 2016, an
XX% increase from the previous year.

Novartis AG generated revenues of $XX billion for the financial year 2016, an XX%
increase from the previous year.
GlaxoSmithKline Plc. generated revenues of $XX billion for the financial year 2016,
an XX% increase from the previous year.
Bayer AG generated revenues of $XX billion for the financial year 2016, an XX%
decrease from the previous year.
LEO Pharma A/S generated revenues of $XX billion for the financial year 2016, an
XX% increase from the previous year.
Company Profile
Johnson & Johnson
Overview
Johnson & Johnson (J&J) was the largest competitor in the dermatology
drugs market in 2017 with a XX% share of the market. The company is
engaged in the development, manufacturing and marketing of personal care
hygienic products, pharmaceuticals and surgical equipment. J&J was
founded in 1886 and is headquartered at New Jersey, USA.
Products and Services
J&J operates through the following business divisions –
The Consumer division offers
The Pharmaceutical division offers products in
The Medical Devices And Diagnostics division manufactures products used
by
Strategy
Johnson & Johnson aims to grow its geographic footprint and increase
investments in emerging markets and developed markets such as Japan. In
2016, the company spent $9.1 billion in R&D.liv With prioritized
investments in internal R&D, strategic licensing arrangements, partnerships
and select acquisitions, the company intends to build a robust product
pipeline for

Financial Performance
Johnson & Johnson’s Beauty section in Consumer division, involved in
dermatology drugs manufacturing, generated revenues of $3.9 billion for the
financial year 2016, a 7.3% increase from the previous year. The company
had market
Allergan Plc
Overview
Products and Services
Strategy
Financial Performance
Galderma S.A
Overview
Products and Services
Strategy
Financial Performance
Novartis AG
Overview
Products and Services
Strategy
Financial Performance
GlaxoSmithKline Plc
Overview
Products and Services
Strategy
Financial Performance